Moran Wealth Management LLC Acquires 1,366 Shares of Zoetis Inc. (NYSE:ZTS)

Moran Wealth Management LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.1% in the 4th quarter, Holdings Channel reports. The firm owned 66,596 shares of the company’s stock after acquiring an additional 1,366 shares during the period. Moran Wealth Management LLC’s holdings in Zoetis were worth $10,850,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. State Street Corp lifted its holdings in shares of Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after acquiring an additional 95,856 shares during the last quarter. Geode Capital Management LLC raised its position in Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Zoetis by 8.5% during the fourth quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock worth $906,202,000 after purchasing an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC boosted its holdings in shares of Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after purchasing an additional 194,542 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Finally, Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $170.34 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a 50-day moving average price of $166.72 and a 200-day moving average price of $176.74.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.